News

Learn about the calprotectin marker and explore different perspectives : the research lab, clinical value and assay end user experience.

BÜHLMANN Laboratories AG (“BÜHLMANN”) announces the closing of the acquisition by funds advised by KLAR Partners Limited (“KLAR Partners” or “KLAR”) today June 5th, 2024. The acquisition enables BÜHLMANN to support its future as a leading independent specialty in-vitro diagnostics company.

Discover the latest advancements from the EAACI 2023 Congress in Hamburg, featuring three insightful posters on the Basophil Activation Test. Topics include validation studies, technical cut-offs, and automated gating strategies.

From gastroenterology to neuroimmunology, read the newest developments from BÜHLMANN in our posters presented at the WorldLab 2024!